Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion

Ming He Huang, Yewen Wu, Vincent Nguyen, Saurabh Rastogi, Bradley K. McConnell, Cori Wijaya, Barry F. Uretsky, Kian Keong Poh, Huay Cheem Tan, Kenichi Fujise

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: The present study determined whether late-ischemia/early reperfusion therapy with the β1-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). Methods and Results: In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5min of ischemia to the first 5min of reperfusion). LV-IS were 48.9±8.9%, 41.5±5.4%, 25.8±7.7% and 16.8±7.3% for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n=12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p<0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5%, 13.3%, and 16.8%, respectively, compared with saline (p<0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22%, 28% and 59%, respectively, compared with saline (n=6, p<0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22%, 37% and 60%, respectively, compared with saline (p<0.01). Conclusions: Late-ischemia/early reperfusion therapy with esmolol+milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume25
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Milrinone
Reperfusion
Ischemia
Therapeutics
Muscle Cells
esmolol
Secondary Prevention
Phosphotransferases
Type 3 Cyclic Nucleotide Phosphodiesterases

Keywords

  • Akt
  • Esmolol
  • Milrinone
  • PKA
  • Reperfusion injury

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. / Huang, Ming He; Wu, Yewen; Nguyen, Vincent; Rastogi, Saurabh; McConnell, Bradley K.; Wijaya, Cori; Uretsky, Barry F.; Poh, Kian Keong; Tan, Huay Cheem; Fujise, Kenichi.

In: Cardiovascular Drugs and Therapy, Vol. 25, No. 3, 06.2011, p. 223-232.

Research output: Contribution to journalArticle

Huang, MH, Wu, Y, Nguyen, V, Rastogi, S, McConnell, BK, Wijaya, C, Uretsky, BF, Poh, KK, Tan, HC & Fujise, K 2011, 'Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion', Cardiovascular Drugs and Therapy, vol. 25, no. 3, pp. 223-232. https://doi.org/10.1007/s10557-011-6302-z
Huang, Ming He ; Wu, Yewen ; Nguyen, Vincent ; Rastogi, Saurabh ; McConnell, Bradley K. ; Wijaya, Cori ; Uretsky, Barry F. ; Poh, Kian Keong ; Tan, Huay Cheem ; Fujise, Kenichi. / Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. In: Cardiovascular Drugs and Therapy. 2011 ; Vol. 25, No. 3. pp. 223-232.
@article{1ecf5e5fa1dd4061909c0b2889a8177c,
title = "Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion",
abstract = "Introduction: The present study determined whether late-ischemia/early reperfusion therapy with the β1-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). Methods and Results: In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5min of ischemia to the first 5min of reperfusion). LV-IS were 48.9±8.9{\%}, 41.5±5.4{\%}, 25.8±7.7{\%} and 16.8±7.3{\%} for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n=12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p<0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5{\%}, 13.3{\%}, and 16.8{\%}, respectively, compared with saline (p<0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22{\%}, 28{\%} and 59{\%}, respectively, compared with saline (n=6, p<0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22{\%}, 37{\%} and 60{\%}, respectively, compared with saline (p<0.01). Conclusions: Late-ischemia/early reperfusion therapy with esmolol+milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.",
keywords = "Akt, Esmolol, Milrinone, PKA, Reperfusion injury",
author = "Huang, {Ming He} and Yewen Wu and Vincent Nguyen and Saurabh Rastogi and McConnell, {Bradley K.} and Cori Wijaya and Uretsky, {Barry F.} and Poh, {Kian Keong} and Tan, {Huay Cheem} and Kenichi Fujise",
year = "2011",
month = "6",
doi = "10.1007/s10557-011-6302-z",
language = "English (US)",
volume = "25",
pages = "223--232",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion

AU - Huang, Ming He

AU - Wu, Yewen

AU - Nguyen, Vincent

AU - Rastogi, Saurabh

AU - McConnell, Bradley K.

AU - Wijaya, Cori

AU - Uretsky, Barry F.

AU - Poh, Kian Keong

AU - Tan, Huay Cheem

AU - Fujise, Kenichi

PY - 2011/6

Y1 - 2011/6

N2 - Introduction: The present study determined whether late-ischemia/early reperfusion therapy with the β1-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). Methods and Results: In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5min of ischemia to the first 5min of reperfusion). LV-IS were 48.9±8.9%, 41.5±5.4%, 25.8±7.7% and 16.8±7.3% for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n=12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p<0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5%, 13.3%, and 16.8%, respectively, compared with saline (p<0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22%, 28% and 59%, respectively, compared with saline (n=6, p<0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22%, 37% and 60%, respectively, compared with saline (p<0.01). Conclusions: Late-ischemia/early reperfusion therapy with esmolol+milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.

AB - Introduction: The present study determined whether late-ischemia/early reperfusion therapy with the β1-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). Methods and Results: In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5min of ischemia to the first 5min of reperfusion). LV-IS were 48.9±8.9%, 41.5±5.4%, 25.8±7.7% and 16.8±7.3% for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n=12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p<0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5%, 13.3%, and 16.8%, respectively, compared with saline (p<0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22%, 28% and 59%, respectively, compared with saline (n=6, p<0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22%, 37% and 60%, respectively, compared with saline (p<0.01). Conclusions: Late-ischemia/early reperfusion therapy with esmolol+milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.

KW - Akt

KW - Esmolol

KW - Milrinone

KW - PKA

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=79958282048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958282048&partnerID=8YFLogxK

U2 - 10.1007/s10557-011-6302-z

DO - 10.1007/s10557-011-6302-z

M3 - Article

VL - 25

SP - 223

EP - 232

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -